Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Posters by Title

Type your Poster Title, then hit apply

Showing 1,267 results.

Thumbnail for Fitness-Based Induction Selection and Outcomes in Adult Acute Myeloid Leukemia at a Tertiary Cancer Center in Southern California

AML - 1566

Fitness-Based Induction Selection and Outcomes in Adult Acute Myeloid Leukemia at a Tertiary Cancer Center in Southern California

Jerry Qi

Poster Presenter: Jerry Qi

Thumbnail for Five-Year Survival Outcomes and Demographic Predictors in Marginal Zone Lymphoma: A SEER-Based Analysis

IBCL - 035

Five-Year Survival Outcomes and Demographic Predictors in Marginal Zone Lymphoma: A SEER-Based Analysis

Berkha Rani

Poster Presenter: Berkha Rani

Thumbnail for Fixed Duration Subcutaneous Mosunetuzumab had Better Practice Efficiency versus Treat-To-Progression Subcutaneous Epcoritamab in Third-Line or Later Follicular Lymphoma: An Economic Analysis

Previous 1...50 51 52 53 54 55 56...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

IBCL - 334

Fixed Duration Subcutaneous Mosunetuzumab had Better Practice Efficiency versus Treat-To-Progression Subcutaneous Epcoritamab in Third-Line or Later Follicular Lymphoma: An Economic Analysis

Wenny Lin

Poster Presenter: Wenny Lin

Thumbnail for Fludarabine/Melphalan Versus Fludarabine/Busulfan Conditioning in AML Undergoing Allogeneic HCT

AML - 1080

Fludarabine/Melphalan Versus Fludarabine/Busulfan Conditioning in AML Undergoing Allogeneic HCT

Aakriti Adhikari

Poster Presenter: Aakriti Adhikari

Thumbnail for Fondaparinux vs Argatroban for Heparin-Induced Thrombocytopenia in Patients With Hematologic Malignancies: A Propensity-Matched Real-World Analysis

CLL - 895

Fondaparinux vs Argatroban for Heparin-Induced Thrombocytopenia in Patients With Hematologic Malignancies: A Propensity-Matched Real-World Analysis

Ahmed Abbasi

Poster Presenter: Ahmed Abbasi

Thumbnail for Forecasting the Durability of Overall Survival Benefit With Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: A Cumulative and Forecast Meta-Analysis

AML - 1421

Forecasting the Durability of Overall Survival Benefit With Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: A Cumulative and Forecast Meta-Analysis

FNU Sagar

Poster Presenter: FNU Sagar

Thumbnail for Frailty and Outcomes With CAR-T Cell Therapy and Bispecific Antibodies in Hematologic Malignancies: A Scoping Review

ABCL - 1668

Frailty and Outcomes With CAR-T Cell Therapy and Bispecific Antibodies in Hematologic Malignancies: A Scoping Review

Yagnapriya Chirrareddy

Poster Presenter: Yagnapriya Chirrareddy

Thumbnail for Frailty and Survival Outcomes in Adult Acute Lymphoblastic Leukemia: A Real-World TriNetX Analysis

ALL - 380

Frailty and Survival Outcomes in Adult Acute Lymphoblastic Leukemia: A Real-World TriNetX Analysis

Nayanika Tummala

Poster Presenter: Nayanika Tummala

Thumbnail for Frailty as a Predictor of 30-Day Readmission in CAR-T Therapy Recipients

CT - 871

Frailty as a Predictor of 30-Day Readmission in CAR-T Therapy Recipients

Danielle Thor

Poster Presenter: Danielle Thor

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors